Table 1 Characteristics of cases with difficult cannulation
Item, n(%)
|
No/Percentage
|
Gender (M: F)
|
41: 37
|
Age, mean (SD)
|
69.6 (13.5)
|
ERCP indication
|
|
CBD stone
|
38(48.7%)
|
Pancreatic tumor/cancer
|
23(29.5%)
|
Cholangiocarcinoma
|
4 (5.2%)
|
Others
|
13 (16.6%)
|
Procedures
|
|
NKF
|
47(60.3%)
|
TPS
|
31(39.7%)
|
No. of deep cannulation achieved
|
62(79.5%)
|
Complications
|
|
Bleeding
|
5(6.4%)
|
PEP
|
8(10.3%)
|
Acute cholangitis
|
2(2.6%)
|
Perforation
|
0(0%)
|
TPS: Transpancreatic sphincterotomy, NKF: needle knife fistulotomy, ERCP: Endoscopic retrograde cholangiopancreaticography, PEP: post-ERCP pancreatitis, CBD: common bile duct
Table 2 Comparison of NKF and TPS groups
|
TPS (n = 31)
|
NKF (n = 47)
|
p
|
Male, n (%)
|
14 (45.2)
|
27 (57.5)
|
0.28
|
Age, mean (SD)
|
71.2 (14.5)
|
68.5 (12.9)
|
0.39
|
ERCP indication
|
CBD stone, n (%)
|
19 (61.3)
|
20(42.6)
|
0.11
|
Pancreatic neoplasm, n (%)
|
8 (25.8)
|
15(31.9)
|
0.56
|
Cholangiocarcinoma, n (%)
|
2 (6.5)
|
2(4.3)
|
0.67
|
Others (CP, other
malignancy) , n (%)
|
2 (6.5)
|
10(21.3)
|
0.08
|
Pancreatic duct – cannulation
|
P – cannulation < 3, n (%)
|
6(19.4)
|
43(91.5)
|
< 0.001
|
P – cannulation ≥ 3, n (%)
|
16(51.6)
|
4(8.5)
|
< 0.001
|
P – cannulation > 5, n (%)
|
6 (19.4)
|
0(0)
|
0.002
|
P – cannulation > 8, n (%)
|
2 (9.7)
|
0(0)
|
0.03
|
P – cannulation, median (IQR)
|
4.5 (3)
|
0 (0)
|
0.002
|
Endoscopic finding
|
Diverticulum, n (%)
|
6 (23.1)
|
4 (8.5)
|
0.03
|
Deep cannulation, n (%)
|
Success
|
23 (74.2)
|
39 (83.0)
|
0.34
|
TPS + NKF
|
3 (9.7)
|
|
|
Failure
|
4 (12.9)
|
8 (17)
|
|
Post – cannulation procedure, n (%)
|
EPLBD
|
3 (9.7)
|
5 (10.6)
|
0.891
|
EPBD
|
7 (22.6)
|
5 (10.6)
|
0.15
|
ERBD(plastic stent)
|
8 (25.8)
|
18 (38.3)
|
0.25
|
metallic stent
|
0 (0)
|
6(12.7)
|
0.04
|
Lithotripsy
|
14 (45.2)
|
15 (31.9)
|
0.236
|
PEP prophylaxis, n (%)
|
Nil
|
13 (41.9)
|
34 (72.3)
|
0.007
|
P - stenting
|
4 (12.9)
|
6 (12.8)
|
0.99
|
Gabexate Mesilae
|
12 (38.7)
|
5 (10.6)
|
0.003
|
NSAIDs
|
0
|
2 (4.26)
|
0.24
|
Gabexate Mesilae + NSAIDs
|
5 (16.1)
|
3 (6.4)
|
0.17
|
TPS: Transpancreatic sphincterotomy, NKF: needle knife fistulotomy, ERCP: Endoscopic retrograde cholangiopancreaticography, PEP: post-ERCP pancreatitis, NKP: needle knife papillotomy, CBD: common bile duct, EPBD: endoscopic papillary balloon dilatation(balloon diameter less than 12mm), EPLBD: endoscopic papillary large balloon dilatation(large-diameter balloons (12-20 mm)), ERBD: endoscopic retrograde biliary drainage, NSAID: Non-Steroidal Anti-Inflammatory Drug, CP: chronic pancreatitis
Table 3 Outcomes of NKF and TPS groups
|
TPS(n = 31)
|
NKF(n = 47)
|
p
|
Post-ERCP amylase level > 3 ULN, n(%)
|
9 (29.0)
|
5 (11.9)
|
0.07
|
Post-ERCP lipase level > 3 ULN, n(%)
|
13 (41.9)
|
11 (25.0)
|
0.14
|
Post-ERCP amylase level, median (IQR)
|
155 (260)
|
62 (103)
|
0.01
|
Post-ERCP lipase level, median(IQR)
|
148(590)
|
97(209.5)
|
0.21
|
PEP, n (%)
|
5 (16.1)
|
3 (6.4)
|
0.17
|
Mild
|
5(16.1)
|
3( 6.4)
|
|
Moderate
|
0(0)
|
0(0)
|
|
Severe
|
0(0)
|
0(0)
|
|
Bleeding, n (%)
|
|
|
|
All bleeding
|
1 (3.2)
|
4 (8.5)
|
0.35
|
Significant bleeding
|
1 (3.2)
|
1 (2.1)
|
0.76
|
Acute cholangitis, n (%)
|
0 (0)
|
2 (4.3)
|
0.25
|
Perforation, n (%)
|
0 (0)
|
0 (0)
|
|
Total complication events
(endoscopically bleeding + perforation + PEP + cholangitis), n (%)
|
6(19.3)
|
9(19.1)
|
0.99
|
Total complication events
(significant bleeding + perforation + PEP + cholangitis), n (%)
|
6(19.3)
|
6(12.8)
|
0.51
|
TPS: Transpancreatic sphincterotomy, NKF: needle knife fistulotomy, ERCP: Endoscopic retrograde cholangiopancreaticography, PEP: post-ERCP pancreatitis,
Table 4 Details of PEP patients
No
|
Gender*
|
Age
|
Indication
|
Cannulation methods
|
Pancreatic cannulation
|
Biliary access
|
EPBD
|
Prophylaxis
|
Severity
of PEP
|
1
|
2
|
50-
59
|
CBD stone
|
NKF
|
0
|
Yes
|
Y
|
none
|
Mild
|
2
|
2
|
60-
69
|
Pancreatic cancer
|
NKF
|
0
|
Yes
|
Y
|
none
|
Mild
|
3
|
2
|
80-
89
|
Pancreas head tumor
|
NKF
|
0
|
Yes
|
N
|
none
|
Mild
|
4
|
1
|
60-
69
|
CBD stone
|
TPS
|
4
|
Yes
|
Y
|
NSAID + gabexate
|
Mild
|
5
|
2
|
60-
69
|
Cholangiocarcinoma
|
TPS
|
12
|
No
|
N
|
none
|
Mild
|
6
|
2
|
30-
39
|
CBD stone
|
TPS
|
5
|
Yes
|
N
|
NSAID + gabexate
|
Mild
|
7
|
1
|
40-
49
|
Pancreatic cancer
|
TPS
|
12
|
No
|
N
|
P stent + NSAID + gabexate
|
Mild
|
8
|
1
|
60-
69
|
CBD stone
|
TPS
|
No
|
Yes
|
Y
|
NSAID + gabexate
|
Mild
|
|
|
|
|
|
|
|
|
|
|
|
|
*EPBD: endoscopic papillary balloon dilatation, TPS: Transpancreatic sphincterotomy, NKF: needle knife fistulotomy, NSAID: Non-Steroidal Anti-Inflammatory Drug,
Table 5 Risk factors associated with PEP
|
Univariate analysis
|
Multivariate analysis
|
Factors
|
Odds ratio
|
P
|
Odds ratio
|
P
|
Age < 65
|
0.95 (0.9 – 1.0)
|
0.05
|
0.11 (0.02 – 0.80 )
|
0.03
|
Gender
|
0.51 (0.1 – 2.3)
|
0.37
|
|
|
NKF or TPS
|
3.5 (0.8 – 1.6)
|
0.18
|
11.57 (0.06 – 3.49)
|
0.45
|
No. p cannulation
|
1.3 (1.0 – 1.6)
|
0.03
|
1.4 (0.93 – 2,3)
|
0.09
|
PEP prophylaxis
|
1.6 (0.4 – 6.9)
|
0.53
|
|
|
Diclofenac
|
10.7 (2.1 – 53)
|
0.004
|
|
|
Gabexate mesilate
|
2.3 (0.5 – 10.2)
|
0.12
|
|
|
P-stenting
|
0.9 (0.1 – 8.8)
|
0.97
|
|
|
NSAIDs + FOY
|
16.5 (3.0 – 91.6)
|
0.001
|
|
|
EPBD
|
7.75 (1.6 – 37.2)
|
0.01
|
11.57 (2.19 – 189.61)
|
0.008
|
|
|
|
|
|
|
|
NKF: needle knife fistulotomy, TPS: transpancreatic sphincterotomy, EPBD: endoscopic papillary balloon dilatation, PEP: Post-ERCP pancreatitis